AstraZeneca PLC said Monday that trials on its Vaxzevria Covid-19 vaccine demonstrated strong immune responses following a prolonged second dose interval of up to 45 weeks.
The pharmaceutical company said antibody levels remain elevated for at least one year following a single dose.
AstraZeneca said a longer dosing interval isn't detrimental, but can derive stronger immunity as the level of antibodies were found to be four times higher with a 45-week dosing interval than with a 12-week interval.
A third dose given at least six months after the second boosted antibody levels six-fold, maintained T cell response, and resulted in neutralizing activity against the Alpha, Beta and Delta variants, it said.
"This should come as reassuring news to countries with lower supplies of the vaccine, who may be concerned about delays in providing second doses to their populations. There is an excellent response to a second dose, even after a 10 month delay from the first," said Andrew J Pollard, chief investigator and director of the Oxford Vaccine Group.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.